{"id":662987,"date":"2026-10-23T09:34:25","date_gmt":"2026-10-23T09:34:25","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/662987\/"},"modified":"2026-10-23T09:34:25","modified_gmt":"2026-10-23T09:34:25","slug":"experimental-injection-targets-visceral-fat-in-early-trial","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/662987\/","title":{"rendered":"Experimental Injection Targets Visceral Fat in Early Trial"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" alt=\"\" height=\"600\" src=\"https:\/\/www.newsbeep.com\/ie\/wp-content\/uploads\/2026\/10\/eyJidWNrZXQiOiJsYWJyb290cy1hc3NldHMiLCJrZXkiOiJfcHVibGljXC9fZmlsZXNcL3N5c3RlbVwvY2tcL3RyZW5kaW5nXC9w.jpeg\" width=\"1200\"\/><\/p>\n<p>An experimental injection that triggers fat cells to self-destruct reduced abdominal visceral fat in a small analysis of participants from two phase 2 clinical trials, according to findings presented at the European Association for the Study of Diabetes (EASD) conference in Milan.<\/p>\n<p>Visceral fat accumulates deep inside the abdomen, surrounding internal organs. Excessive amounts are associated with insulin resistance, type 2 diabetes and cardiovascular disease.\u00a0<\/p>\n<p>The drug, CBL-514, is designed to induce apoptosis, a natural process through which cells break down and die. Unlike weight-loss medications that primarily reduce appetite, the injection targets adipocytes, the cells that store fat. CBL-514 has also been investigated for reducing subcutaneous fat, which lies directly beneath the skin.<\/p>\n<p>In the current study, researchers analyzed magnetic resonance imaging (MRI) data from 40 participants who received CBL-514 or a placebo. Participants received injections into the lower abdomen, with treatment continuing for up to 12 weeks.<\/p>\n<p>Four weeks after the final injection, participants treated with CBL-514 had an average 12.01% reduction in visceral fat volume compared with baseline measurements. In contrast, the placebo group experienced an average 5.68% increase.<\/p>\n<p>At a later follow-up, conducted eight to 12 weeks after treatment ended, visceral fat volume remained 10.45% below baseline in the treatment group. Meanwhile, the placebo group experienced an average 11.76% increase.<\/p>\n<p>While promising, the findings do not establish whether reducing fat with the injection improves metabolic health or produces sustained weight loss. The analysis was based on a small subgroup of participants, and detailed results have so far been reported in a conference abstract rather than a full research paper.<\/p>\n<p>The treatment&#8217;s safety also requires further investigation. Previous phase 2 research on CBL-514 found that injection-site reactions were common, including pain, redness and swelling. Although most were mild or moderate, some participants experienced severe injection-site pain.<\/p>\n<p>Researchers are also investigating whether CBL-514 could help people maintain weight loss after stopping glucagon-like peptide-1 (GLP-1) medications. In animal studies, combining CBL-514 with tirzepatide reduced weight regain after treatment ended. Whether this approach works in humans remains unknown.<\/p>\n<p>Ultimately, larger clinical trials will be needed to establish the treatment&#8217;s long-term safety, durability and potential health benefits. Researchers must also determine whether reducing fat beneath the skin and around internal organs affects fat storage elsewhere in the body.<\/p>\n<p>\u00a0<\/p>\n<p>Sources:<a href=\"https:\/\/www.sciencedaily.com\/releases\/2026\/10\/261008102713.htm\" rel=\"nofollow noopener\" target=\"_blank\"> ScienceDaily<\/a>,<a href=\"https:\/\/www.sciencemediacentre.org\/expert-reaction-to-conference-abstract-about-a-phase-2-trial-of-a-new-weight-loss-injection-cbl-514-and-levels-of-subcutaneous-and-visceral-fat-presented-at-the-european-association-for-the-study-o\/\" rel=\"nofollow noopener\" target=\"_blank\"> Science Media Centre<\/a>,<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12080885\/\" rel=\"nofollow noopener\" target=\"_blank\"> Previous phase 2 study<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"An experimental injection that triggers fat cells to self-destruct reduced abdominal visceral fat in a small analysis of&hellip;\n","protected":false},"author":2,"featured_media":662988,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[103,61,60],"class_list":["post-662987","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-ie","tag-ireland"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/662987","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=662987"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/662987\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/662988"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=662987"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=662987"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=662987"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}